Key Takeaways:
Jazz Pharmaceuticals agreed to acquire Actio Biosciences for $820 million upfront, adding a first-in-class therapy for an ultra-rare epilepsy with no approved treatments.
"The acquisition of ABS-1230 represents a highly strategic expansion of our rare epilepsy portfolio, building upon the global success of Epidiolex and deepening our leadership in rare and severe epilepsies," Renee Gala, president and chief executive officer at Jazz Pharmaceuticals, said.
The Dublin-based company will pay up to $500 million more in approval and sales milestones. The deal centers on ABS-1230, an oral small-molecule KCNT1 ion channel inhibitor for KCNT1+ epilepsy, a genetic developmental and epileptic encephalopathy affecting about 2,500 patients in the United States. Most patients endure dozens to hundreds of seizures daily that resist existing antiseizure drugs, and about 80 percent experience disease onset during infancy.
ABS-1230 has FDA Fast Track, Rare Pediatric Disease and Orphan Drug designations and was accepted into the agency's Rare Disease Evidence Principles program, which aims to speed development of ultra-rare disease therapies. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study to support a U.S. new drug application. The transaction, approved by both boards, is expected to close by the fourth quarter of 2026.
At closing, Actio will spin out a new privately held company holding certain assets, including ABS-0871, a clinical-stage TRPV4 inhibitor for Charcot-Marie-Tooth type 2C, and other early-stage programs. Existing investors will fund the new entity, with Jazz taking a minority stake.
ABS-1230 recently showed meaningful seizure reductions in an early proof-of-concept trial in children with KCNT1 epilepsy. In preclinical studies, the drug inhibited KCNT1 across all evaluable pathogenic mutations, suggesting it could treat all patients with the condition. General antiepileptic drugs have limited benefit in this genetic epilepsy and are often tied to debilitating side effects, according to the companies.
Jazz will fund the deal through cash on hand and existing financing facilities. Moelis & Company advised Jazz, with Hogan Lovells Cadwalader US LLP as legal counsel. J.P. Morgan Securities and Centerview Partners advised Actio, with Cooley LLP as legal counsel.
The deal deepens Jazz's rare epilepsy franchise built on Epidiolex, its approved cannabinoid therapy, and gives it a potential first-in-class precision medicine for a devastating pediatric disease. Investors will watch the KYRON trial's data and the transaction's closing, expected by the fourth quarter of 2026, as the next catalysts.
This article is for informational purposes only and does not constitute investment advice.
